GleamWall
中文EN

JNJ JOHNSON & JOHNSON

Pharmaceutical Preparations · NYSE · SEC CIK 200406 · Fiscal year ends 01/03

Financial factors as of 2026-09-27 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY7.8%
TTM net income YoY-35.9%
TTM EPS YoY-36.4%
Revenue 3-yr CAGR5.9%
Net income 3-yr CAGR-22.5%

Margins

Gross margin67.6%
Operating margin—
Net margin16.2%
FCF margin20.7%
EBITDA margin—

Returns

ROE20.0%
ROA8.2%
ROIC (approx.)—
Asset turnover0.51x

Leverage & solvency

Liabilities / assets58.7%
Debt / equity0.55x
Current ratio1.02x
Interest coverage—

Cash quality & payout

Operating cash flow / net income1.63x
Accruals ratio-5.2%
Payout ratio—
Capex / revenue5.6%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-28FY20242024-12-29
Income statement
Revenue$94.19B$88.82B
Cost of revenue$30.26B$27.47B
Gross profit$63.94B$61.35B
R&D expense$109.00M$1.84B
SG&A expense$23.68B$22.87B
Interest expense$971.00M$755.00M
Pretax income$32.58B$16.69B
Income tax$5.78B$2.62B
Net income$26.80B$14.07B
EPS (basic)11.135.84
EPS (diluted)11.035.79
Dividends declared per share5.144.91
Weighted avg. shares (diluted)2.43B2.43B
Balance sheet
Cash & equivalents$19.71B$24.11B
Short-term investments$393.00M$417.00M
Receivables$17.18B$14.84B
Inventory$14.19B$12.44B
Current assets$55.62B$55.89B
PP&E, net$23.17B$20.52B
Goodwill$48.77B$44.20B
Intangibles$50.40B$37.62B
Total assets$199.21B$180.10B
Current liabilities$54.13B$50.32B
Short-term debt$8.49B$6.00B
Long-term debt$39.44B$30.65B
Total debt$47.93B$36.65B
Total liabilities$117.67B$108.61B
Shareholders' equity$81.54B$71.49B
Net debt$28.22B$12.55B
Cash flow statement
Operating cash flow$24.53B$24.27B
Capital expenditure$4.83B$4.42B
Free cash flow$19.70B$19.84B
Investing cash flow-$23.59B-$18.60B
Financing cash flow-$5.54B-$3.13B
Depreciation & amortization$7.50B$7.34B
Stock-based compensation$1.35B$1.18B
Share buybacks$5.95B$2.43B

Free plan shows the latest 2 periods; Pro shows all 19 🔒

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.